Möchten Sie immer auf dem neuesten Stand bleiben?

Pooled Phase 1/2 data show 80% complete remission rate in pediatric R/R T-ALL/LBL patients Global TENACITY-01 study reports 86% overall response rate in adults with R/R T-ALL/LBL BOSTON, June 11,...

TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing Superkines for...

Longeveron (LGVN) granted Small or Medium-sized Enterprise (SME) status by the European Medicines Agency (EMA).

STOCKHOLM, June 09, 2026 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) and the International Myeloma Working Group (IMWG) are proud to announce the recipients of this year’s Robert...

BOSTON, June 09, 2026 (GLOBE NEWSWIRE) -- Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today announced that the U.S. Food and...

Austin, United States, June 09, 2026 (GLOBE NEWSWIRE) -- “According to SNS Insider, the Tissue Engineered Skin Substitutes Market was valued at USD 1.59 billion in 2025 and is projected to reach USD...

LEWES, DELAWARE, June 08, 2026 (GLOBE NEWSWIRE) -- Verified Market Research®, a leading provider of syndicated market intelligence, announces the release of its comprehensive analysis of the Global...

Gastrointestinal prophylaxis reduced Grade ≥ 2 diarrhea/colitis from 55% without prophylaxis to 10% with prophylaxisThe maximum tolerated dose has not yet been determinedNo difference is observed in...

Analyses demonstrate consistent positive signals across endpoints in AKI patientsFindings derived from post hoc analysis of 101 patients also experiencing respiratory distressNew data and analysis to...

Global Oil and Gas SCADA Market Size, Share, Revenue Trends & Segment by Component, Architecture, Deployment Mode, Communication Technology & Forecast 2035